Economic Value Added (EVA)
EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
AmerisourceBergen Corp. pages available for free this week:
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AmerisourceBergen Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
AmerisourceBergen Corp., economic profit calculation
US$ in thousands
| 12 months ended: | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | |
|---|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | |||||||
| Cost of capital2 | |||||||
| Invested capital3 | |||||||
| Economic profit4 | |||||||
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
Net Operating Profit after Taxes (NOPAT)
AmerisourceBergen Corp., NOPAT calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in allowances for returns and credit losses.
3 Addition of increase (decrease) in LIFO reserve. See details »
4 Addition of increase (decrease) in equity equivalents to net income (loss) attributable to AmerisourceBergen Corporation.
5 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
6 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
7 Addition of after taxes interest expense to net income (loss) attributable to AmerisourceBergen Corporation.
8 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
9 Elimination of after taxes investment income.
- Net income (loss) attributable to AmerisourceBergen Corporation
- The net income figures exhibit significant volatility over the analyzed periods. Initially, there is a substantial increase from approximately 364 million USD in 2017 to around 1.66 billion USD in 2018, followed by a notable decline to about 855 million USD in 2019. The year 2020 stands out with a dramatic shift into a net loss of approximately 3.41 billion USD, indicating a severe financial setback. However, recovery occurs in subsequent years, with net income rebounding to nearly 1.54 billion USD in 2021 and increasing slightly to approximately 1.70 billion USD in 2022. This trend suggests a sharp but temporary disruption in profitability, with the company managing to restore positive earnings thereafter.
- Net operating profit after taxes (NOPAT)
- The NOPAT figures mirror the overall pattern observed in net income but show even greater variability. From 2017 to 2019, NOPAT demonstrates consistent growth, increasing from approximately 772 million USD to nearly 1.19 billion USD. In 2020, a significant downturn occurs, with NOPAT plunging into a substantial negative figure of roughly 4.62 billion USD, signaling operational challenges or extraordinary expenses. The company recovers in 2021 and 2022, with NOPAT rising to approximately 1.78 billion USD and further to about 2.39 billion USD, exceeding previous peak levels. This rebound reflects improved operational efficiency or favorable conditions post-2020.
Cash Operating Taxes
AmerisourceBergen Corp., cash operating taxes calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
- Provision (benefit) for income taxes
- The provision for income taxes exhibits significant volatility across the observed periods. Initially, there was a positive provision amounting to 553,403 thousand USD in 2017, followed by a substantial negative provision of -438,469 thousand USD in 2018, indicating a tax benefit during that year. In 2019, the provision returned to a positive amount of 112,971 thousand USD. The year 2020 saw a drastic shift with a large tax benefit of -1,894,273 thousand USD, which is an anomaly compared to other years. Subsequently, the provision reverted to positive amounts, recording 677,251 thousand USD in 2021 and a slightly decreased but still substantial 516,517 thousand USD in 2022. Overall, these fluctuations suggest unpredictable tax outcomes, potentially influenced by changes in tax laws, one-time adjustments, or varying profitability impacts.
- Cash operating taxes
- Cash operating taxes generally demonstrate a more stable yet somewhat varied trend relative to the provision for income taxes. Starting at 288,588 thousand USD in 2017, there was a notable increase to 403,869 thousand USD in 2018. However, 2019 witnessed a sharp decline to 121,219 thousand USD, followed by a negative figure of -316,612 thousand USD in 2020, indicating a refund or tax credit situation in that year. In the subsequent years, 2021 and 2022, the amounts reverted to positive territory at 385,676 and 371,488 thousand USD, respectively, showing consistent tax payments in these periods. The pattern suggests that actual cash tax payments are subject to fluctuations, possibly reflecting timing differences, tax planning measures, or the impact of deferred tax assets and liabilities.
Invested Capital
AmerisourceBergen Corp., invested capital calculation (financing approach)
US$ in thousands
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of allowance for doubtful accounts receivable.
4 Addition of LIFO reserve. See details »
5 Addition of equity equivalents to total AmerisourceBergen Corporation stockholders’ equity (deficit).
6 Removal of accumulated other comprehensive income.
- Total reported debt & leases
-
The total reported debt and leases exhibited a rising trend from 2017 to 2018, increasing from approximately 3.7 billion to 4.8 billion US dollars. This amount remained relatively stable in 2019 and 2020 around 4.6 billion before experiencing a significant spike in 2021, reaching approximately 7.8 billion. In 2022, the debt level decreased to about 6.7 billion, yet remained substantially higher than the levels observed prior to 2021.
- Total stockholders’ equity (deficit)
-
Stockholders' equity showed steady growth from 2017 to 2018, increasing from about 2.1 billion to 2.9 billion US dollars, and remained close to this level in 2019. However, there was a sharp decline in 2020, resulting in a deficit position of approximately -1.0 billion US dollars. The equity recovered slightly in 2021, reaching a positive 223 million, but reverted to a negative equity balance of approximately -212 million in 2022. This pattern reflects significant volatility and financial stress within the period analyzed.
- Invested capital
-
Invested capital increased steadily from 2017 through 2019, rising from roughly 10.9 billion to 12.3 billion US dollars. In 2020, it declined sharply to about 7.1 billion, representing a significant reduction. The invested capital then rebounded notably in 2021, climbing back to approximately 12.9 billion, and showed marginal growth in 2022, reaching about 13.0 billion. This fluctuation indicates a substantial reallocation of capital resources particularly around 2020.
Cost of Capital
AmerisourceBergen Corp., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2020-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2019-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 24.50%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 24.50%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2018-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Debt3 | ÷ | = | × | × (1 – 35.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 35.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2017-09-30).
1 US$ in thousands
2 Equity. See details »
3 Debt. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
AmerisourceBergen Corp., economic spread ratio calculation, comparison to benchmarks
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Economic profit1 | |||||||
| Invested capital2 | |||||||
| Performance Ratio | |||||||
| Economic spread ratio3 | |||||||
| Benchmarks | |||||||
| Economic Spread Ratio, Competitors4 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| Medtronic PLC | |||||||
| UnitedHealth Group Inc. | |||||||
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Economic profit. See details »
2 Invested capital. See details »
3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
Economic Profit Margin
AmerisourceBergen Corp., economic profit margin calculation, comparison to benchmarks
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Economic profit1 | |||||||
| Revenue | |||||||
| Performance Ratio | |||||||
| Economic profit margin2 | |||||||
| Benchmarks | |||||||
| Economic Profit Margin, Competitors3 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| Medtronic PLC | |||||||
| UnitedHealth Group Inc. | |||||||
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Economic profit. See details »
2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =
3 Click competitor name to see calculations.